Navigation Links
Low Occurrence of Severe Cardiac Side Effects Despite Extensive Prior Doxorubicin Treatment Reported in Pixantrone Pivotal Trial
Date:5/19/2009

;=300 mg/m2 5.6% 2/68 500 mg/m2 15% 2/43 600 mg/m2 32% 0/36 >600 48% 1/25 (1) Cancer 97: 2869, 2003

The EXTEND clinical trial was a phase III single-agent trial of pixantrone for patients with relapsed, aggressive NHL who received two or more prior therapies and who were sensitive to treatment with anthracyclines. The trial enrolled 140 patients and patients were randomized to receive either pixantrone or another single-agent drug currently used for the treatment of this patient population and selected by the physician.

CTI previously announced that its pivotal phase III (PIX 301) EXTEND trial had achieved its primary endpoint with patients randomized to treatment with pixantrone achieving a significantly higher rate of confirmed (CR) and unconfirmed complete remissions (CRu) compared to patients treated with standard chemotherapy (14/70 (20.0%) for pixantrone arm compared to 4/70 (5.7%) for the standard chemotherapy arm, p = 0.02) with no patients in the standard chemotherapy arm achieving a confirmed complete remission.

Pixantrone recipients had a low incidence of severe neutropenia complicated by either fever or documented infections, or severe vomiting or diarrhea. Pixantrone patients also experienced a low incidence of hair loss, a very common side effect of other drugs in this class. Overall, the incidence of serious adverse events was similar between pixantrone and the control arm. The pixantrone patients had a higher incidence of leucopenia and neutropenia. Disease progression reported as an adverse event was less frequent in the pixantrone than in the control arm (1.5% vs. 13.4%).

CTI will be presenting additional new efficacy and safety data at the u
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Pierre Fabre Dermatologie Starts Clinical Trials on a Beta-Blocker to Treat Severe Infantile Haemangioma
2. Amorcyte Reports Phase I Results of AMR-001 to Improve Recovery From Severe Heart Attack at ACC Annual Scientific Session
3. New Biologic STELARA(TM) Receives Approval in Europe for Treatment of Moderate to Severe Plaque Psoriasis
4. New Data Suggest CIMZIA(R) (Certolizumab Pegol) Active in Treating Moderate to Severe Crohns Patients With Fistulizing Disease
5. Dry Eye Survey: Ophthalmologists Cite Treatment Limitations/Gaps in Treatment of Moderate to Severe Dry Eye
6. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
7. Video: New Survey Shows Three in Four School Nurses Have Students at Risk for Severe Allergic Reactions Who Do Not Bring Auto-Injectable Epinephrine to School
8. Tanning and Excessive Sun Exposure Can Cause Severe Damage to Eyes
9. Cryolife Once Again Severely Maims an Innocent Knee Surgery Patient
10. Abbotts HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis
11. Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... the entire body to visualize long-range connections between cells ... long-time dream of biologists. A study published by ... Cell has now made that dream a reality, ... human tissue biopsies transparent, while keeping the cellular structures ... for a better understanding of brain-body interactions, more accurate ...
(Date:7/31/2014)... July 31, 2014 According to ... "Quantum Dots Market - Global Industry Analysis, Size, Share, ... was valued at USD 88.5 million in 2011, which ... growing at a CAGR of 53.8% from 2013 to ... Report at  http://www.transparencymarketresearch.com/quantum-dots.html Increasing demand for ...
(Date:7/31/2014)... According to a new market ... Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG ... Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, ... the global electrodes market for medical devices was valued ... to reach a market worth USD 1,451.2 million in ...
(Date:7/31/2014)... , July 31, 2014  Smith & ... global medical technology business, today announced its entry ... the HAT-TRICK™ Lesser Toe Repair System. Comprised of ... products for metatarsophalangeal (MTP) ligament repair and reconstruction, ... implant for proximal Inter-phalanges (PIP) fusion, also known ...
Breaking Biology Technology:See-through organs and bodies will accelerate biomedical discoveries 2Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 2Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 3Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 4Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 2Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 3Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 4Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 5Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 6Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 2Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 3Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 4
... with safflower-produced insulin and ... ... CALGARY, April 7 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc.,(TSX:SBS), a biotechnology company ... announced that it,has received milestone payments totaling CDN$850,000 from AVAC Ltd. ...
... CPHD ) will announce financial results for ... Thursday, May 1, 2008. The announcement will be,followed ... afternoon at 4:30 p.m.,Eastern Time., John Bishop, ... Financial Officer and Michael Myhre, Vice President,Corporate Controller, ...
... Meeting Summary: Genmab to hold Annual General ... Genmab A/S (OMX:,GEN) summon the Annual General Meeting on ... SAS Scandinavia Hotel, Amager Boulevard 70, 2300,Copenhagen S, Denmark., ... the Company,s activities during,the year., 2. Presentation of the ...
Cached Biology Technology:SemBioSys receives milestone payments from AVAC Ltd. 2SemBioSys receives milestone payments from AVAC Ltd. 3SemBioSys receives milestone payments from AVAC Ltd. 4Cepheid Schedules Teleconference and Webcast for First Quarter 2008 Results 2Genmab A/S - Notice to Convene Annual General Meeting 2Genmab A/S - Notice to Convene Annual General Meeting 3Genmab A/S - Notice to Convene Annual General Meeting 4Genmab A/S - Notice to Convene Annual General Meeting 5Genmab A/S - Notice to Convene Annual General Meeting 6Genmab A/S - Notice to Convene Annual General Meeting 7
(Date:7/31/2014)... important step has been made to help better identify and ... an abnormal narrowing and enlarging of medium sized arteries in ... and other organs causing damage. In a new report appearing ... , scientists provide evidence that that FMD may not ... they show a connection to abnormalities of bones and joints, ...
(Date:7/31/2014)... found that bacteria in the Gulf of Mexico consumed ... during the Deepwater Horizon spill in the months after ... In two new studies conducted in a deep sea ... bacteria called Colwellia likely consumed gaseous hydrocarbons ... were released as part of the oil spill. ...
(Date:7/31/2014)... new meta-analyses involving tree nuts (almonds, Brazil nuts, cashews, ... recently published in the online publications, British Medical ... ONE (ii). The BMJ Open article ... syndrome (MetS) criteria and showed that tree nut consumption ... blood glucose. The PLOS ONE article focused ...
Breaking Biology News(10 mins):Scientists discover biochemical mechanisms contributing to fibromuscular dysplasia 2New international tree nut council study looks at nuts, diabetes and metabolic syndrome 2
... to the slate of expertswhich includes military medical ... Partnerships, on September 23, 2010, at the Omni ... a premier opportunity for representatives of the public ... medical partnerships to benefit our nation,s wounded warriors ...
... biodiversity, a combination of conventional farming and protected areas ... production and protect wildlife. The findings come from ... scientists at the Universities of Leeds and York. They ... farms, but that a conventional farm plus an area ...
... (PV) cells world-wide produced a peak amount of electricity estimated ... in Europe. Similarly to previous years, this shows the EU,s ... solar systems were installed. By the end of 2009, Europe,s ... was 16 GW, which is about 70% of the world,s ...
Cached Biology News:Sutherland and Berglass to keynote USU-HJF Military Medicine Symposium 2Sutherland and Berglass to keynote USU-HJF Military Medicine Symposium 3Is organic farming good for wildlife? It depends on the alternative 2Is organic farming good for wildlife? It depends on the alternative 3Three-quarters of new solar systems worldwide were installed in the EU in 2009 2Three-quarters of new solar systems worldwide were installed in the EU in 2009 3
... DNA Visualizer DX's sensitivity of DNA detection ... DNA band in an agarose gel can be ... this kit can be purified by organic solvent ... tested commercially kits worked well.) DNA excised ...
...
Mouse monoclonal antibody raised against a full length recombinant CSNK2A2. NCBI Entrez Gene ID = CSNK2A2...
... conserved form of cell suicide, which follows ... component of this process is a cascade ... enzymes participate in a series of reactions ... signals and result in the cleavage of ...
Biology Products: